Perimeter Schedules Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 31st; Provides Corporate Update
Rhea-AI Summary
Perimeter Medical Imaging AI (OTCQX: PYNKF) will report fourth quarter and full year 2025 results after market close on March 31, 2026 and will host a webcast and conference call at 5:00 pm ET.
The company also entered a warrant cancellation agreement with Social Capital, surrendering 14,466,667 warrants for no consideration, reducing Social Capital's partially‑diluted stake from 30% to 22.3% (non‑diluted stake remains 22.2%).
Positive
- 14,466,667 warrants surrendered, cutting potential dilution
- Social Capital partially‑diluted ownership reduced from 30% to 22.3%
- Earnings call scheduled March 31, 2026 at 5:00 pm ET (webcast available)
Negative
- Warrants surrendered for no consideration, no cash inflow from cancellation
- Remaining 115,214 warrants still outstanding could dilute if exercised
Fourth Quarter and Full Year 2025 Results Conference Call Details:
Date: | Tuesday, March 31, 2026 |
Time: | 5:00 pm Eastern Time |
Dial-In Numbers: | 1-800-717-1738 ( |
The call will also be broadcast live and archived on the Company's website here.
Warrant Cancellation Agreement
The Company also announces that it has entered into a warrant cancellation agreement (the "Warrant Cancellation Agreement") with SC Master Holdings LLC ("Social Capital"), pursuant to which Social Capital has agreed to surrender 14,466,667 common share purchase warrants (the "Warrants") of the Company for cancellation, for no consideration.
Early Warning Disclosure as a Result of the Warrant Cancellation
Prior to the cancellation of the Warrants, Social Capital owned 29,089,337 common shares and 14,581,881 Warrants representing
Social Capital holds the Perimeter common shares and Warrants for investment purposes.
The foregoing disclosure is being disseminated pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting. A copy of the report to be filed with Canadian securities regulators in connection with the cancellation of the Warrants will be available on Perimeter's SEDAR+ profile at www.sedarplus.com and a copy may be obtained by contacting Perimeter as noted under "Contacts" below.
About Perimeter Medical Imaging AI, Inc.
Based in
Indications for Use: The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.
The Claire OCT System should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant, or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labeling for full safety information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CONTACTS:
Stephen Kilmer
Investor Relations
Direct: 647-872-4849
Email: skilmer@perimetermed.com
Adrian Mendes
Chief Executive Officer
Toll-free: 888-988-7465 (PINK)
Email: investors@perimetermed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/perimeter-schedules-fourth-quarter-and-full-year-2025-financial-results-conference-call-for-march-31st-provides-corporate-update-302722488.html
SOURCE Perimeter Medical Imaging AI Inc.
FAQ
What did Perimeter (PYNKF) announce for its March 31, 2026 earnings call?
How many warrants did Social Capital surrender in the Perimeter (PYNKF) cancellation?
How did the warrant cancellation affect Social Capital's ownership in Perimeter (PYNKF)?
Will Perimeter (PYNKF) receive cash from the warrant cancellation with Social Capital?
When and how can investors access Perimeter's March 31, 2026 webcast for results?
